Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Odrick Rosas

Physical Medicine & Rehabilitation Toa Alta, PR Medical Doctor

NPI 1477940500 CMS profile 2774258

Calle 1 A1 Urb San Fernando, Toa Alta, PR 00954

Open in the dashboard

General payments

$1,026

14 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Odrick Rosas of Toa Alta, PR is reported in the CMS Open Payments database as having received $1,026 across 14 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $125 1
2022 General $71 1
2021 General $123 1
2020 General $20 1
2019 General $687 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Odrick Rosas
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Odrick Rosas were reported at $0. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Odrick Rosas Physical Medicine & Rehabilitation median Middle half National median
2019 $687 $133 $45–$390 $163
2020 $20 $88 $29–$272 $114
2021 $123 $116 $33–$360 $132
2022 $71 $123 $40–$378 $149
2023 $125 $131 $43–$396 $160
2024 $0 $141 $45–$409 $164
2025 $0 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $248 2 payments
  2. Janssen Pharmaceuticals, Inc $240 4 payments
  3. Ferring Pharmaceuticals Inc. $125 1 payment
  4. Sanofi-Aventis U.S. LLC $100 1 payment
  5. Mitsubishi Tanabe Pharma America, Inc. $96 1 payment
  6. Merck Sharp & Dohme Corporation $78 1 payment
  7. Bard Peripheral Vascular, Inc. $71 1 payment
  8. Pfizer Pharmaceuticals LLC $29 1 payment
  9. PTC Therapeutics, Inc. $28 1 payment
  10. AbbVie, Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,026 14 payments
Products named General payments · program years 2019–2023
  1. FARXIGA $248 2 payments
  2. INVOKANA $140 3 payments
  3. EUFLEXXA $125 1 payment
  4. XARELTO $120 2 payments
  5. TOUJEO $100 1 payment
  6. Radicava $96 1 payment
  7. STEGLATRO $78 1 payment
  8. ELIQUIS $29 1 payment
  9. EMFLAZA $28 1 payment
  10. INVOKAMET $20 1 payment
  11. Other $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

575

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$8,520

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

12.3%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Er Diclofenac Sodium Brand 71 $2,974
Diclofenac Potassium Generic 58 $1,731
Triamcinolone Acetonide Generic 72 $728
Dexamethasone Generic 89 $690
Sulindac Generic 46 $494
Diclofenac Sodium Generic 39 $459
Meloxicam Generic 79 $338
Celecoxib Generic 19 $284
Duloxetine Hcl Generic 19 $244
Methylprednisolone Generic 26 $235

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$5,711

Medicare's payments for the services billed

Medicare patients

24

Average age 77

Services billed

72

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 75%
Chronic kidney disease 50%
Cancer 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

14 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record